Alaster Stockwell-Jones

Following Microba’s acquisition of Invivo Healthcare and the migration of Microbiome Explorer, our metagenomic NGS gut test from Invivo to Microba, I have accepted the role of Managing Director - UK for Microba. Microba Life Sciences is a precision microbiome company driven to improve health. We are powering the discovery of new relationships between the gut microbiome, health and disease for the development of new health solutions. With world-leading technology for measuring the gut microbiome, we are driving the discovery and development of novel therapeutics for chronic diseases and delivering diagnostic testing services globally to clinicians, their patients and researchers.

Group Commercial Director for invivo healthcare, one of the leading microbiome testing and supplements B Corp businesses, recently acquired by Microba, an international leader in microbial genomics. Microba's world-leading precision metagenomic technology, enables specialists and clinicians to elevate clinical diagnoses, decision-making and standard of care.

Founding board member of The International Medical Device Distributors Association (INTMEDA). Since founding INTMEDA we have grown rapidly to become one of the largest specialist Medical Device Distribution Associations in the world. Our association has 48 members with a commercial presence in 45 countries, spanning 5 continents and 20+ therapeutics areas. We: • Connect Medical Devices distributors all over the world • Help our members grow their business • Provide a myriad of Medical Device industry insights

Rothschilds 5 Arrows PE owned BioPharma scale up. Headhunted to design and lead the scale-up of the MedTech business as a member of the global senior leadership team. BioPhorum has become the trusted environment where senior leaders of biopharmaceutical and Medical Device companies come together to openly share and discuss the emerging trends and challenges facing their industries.

Initially, we created GENETIX Healthcare as a vehicle to get stuck into designing solutions that would help accelerate personalised and preventative health and wellness - the future of healthcare. With the onset of the COVID-19 pandemic in late 2019, we decided to build, spin out and rapidly scale a COVID-19 diagnostic testing company. We worked closely with some of the largest diagnostic testing providers as well as pioneering startups. Our portfolio of Dx tests included: RT-qPCR (Saliva and NPS), fixed lab and mobile service offerings, Rapid Antigen (LFT) and Rapid Antibody (IgG & IgM). We grew quickly to help protect people, communities, businesses and schools from COVID-19 in multiple countries. The accelerating adoption of microbiome testing and precision intervention, genetic and epigenetic testing, the digitalisation and democratisation of end-2-end clinical research platforms, Ai, ML, AR & VR, will present fascinating opportunities to further improve patient outcomes, improve quality and quantity of life and drive improvements in value based care. With greater access to highly accurate diagnostic tests (e.g., microbiome, genetic, epigenetic) we see a future world where disease is increasingly prevented rather than cured.

PE owned global MedTech turnaround and scale up. Headhunted to lead the design and transformation of a global MedTech organisation. Responsible for all direct and indirect commercial operations spanning 72 countries serviced through 5 global offices located in the US, UK, EMEA and APAC. Responsibilities and experiences: Broader and enhanced portfolio of responsibilities including: global sales, marketing, customer services with additional responsibility for clinical support and involvement in the identification of new product development opportunities. • Board level (two Private Equity owners, company Directors and NED's) • Private Equity Fundraising • MBO: Sale of the MedArt Laser Business Unit to the management team (Denmark) • Full P&L accountability • Initiated and lead a new performance driven culture across the business • Product portfolio rationalisation • USA relaunch and new team build • Rapid expansion into EMEA and APAC through new distribution partners • Year 1: Arrested revenue and profit decline posting 5% revenue growth and +ve EBITDA • Year 2: 50% revenue growth with corresponding EBITDA growth YoY • Secured new contracted recurring revenue streams in USA, EMEA and APAC

Headhunted to lead the commercial turnaround of a global SME Medical Device business with a presence in 72 countries serviced through 5 regional offices in the USA, UK, Germany, Denmark and Indonesia. Initially responsible for sales and customer services globally.

World first, High Net Worth and family office backed MedTech startup launching the first ever generic hip implant. Headhunted to lead the U.K. business as Managing Director. Core responsibilities and experiences: • Highly disruptive and innovative HNW backed Medical Device Start up • Creation of the world’s first 'Generic' Hip implant system • UK Managing Director, member of the senior leadership team and employee #1 • New product, new orthopaedic implant category, new team and new business build • Full P&L responsibility We created the highly innovative idea to build an entirely new implant product category within the established orthopaedic market. We were the first company in the world to develop and market Optimised Equivalent® hip implants that unlocked significant value to National and Private Healthcare Systems.

Promoted to UK Commercial Manager Responsibilities and experience: • Commercial responsibility for sales of 54,000 products, including orthopaedic implants, trauma, CMF, endoscopy, laparoscopy and integrated operating theatres, into the major private hospital providers in the UK: BMI Healthcare, Spire Healthcare, Nuffield, Ramsay Healthcare, Aspen Healthcare, Circle Health and Care UK • £22.1M pa business unit with sales growing at +12% YoY • Valuable experience of how a Fortune 500 Medical Device company with multiple siloed business units and a highly complex matrix structure manages and grows a business. • European Project Management Team for Stryker Connect: Stryker's first internal Social Network to help foster enhanced collaboration across siloed business units. • Valuable experience of how a Fortune 500 Medical Device company manages the business. In 2021 Stryker was named in the Top 10 of global Medical Device companies with 50,000+ product lines, 40,000+ employees, a presence in 100+ countries and $14B+ revenues.

Promoted to UK Key Account Manager

Creation of a new Cardiology diagnostic company to: • Help increase access to gold standard cardiac diagnostics using ultra-portable platforms • Help improve diagnostic capability and infrastructure in primary care • Help provide a wider choice of diagnostic provider closer to people homes

Responsibilities and experience: National Sales Manager for GE Healthcare's portfolio of cardiology diagnostic products, services, and solutions in the UK. • Launch of the first, high functionality, ultra-portable, desktop cardiac diagnostic system, the Vivid-i. • Valuable experience of how a Fortune 500 Medical Device company with multiple siloed business units and a highly complex matrix structure manages and grows a business. In 2021 GE healthcare was named in the Top 10 of global Medical Device companies with a broad product portfolio, 50,000+ employees, a presence in 100+ countries and $18B revenues.

1st Line Management responsibility for a team of 10 GP, PCT, SHA & Hospitals specialists In 2021 Eli Lilly was named in the Top 5 global biopharmaceutical companies

Modules covered: Burden & Harm | Quality Variation | Legal Systems & Regulations | Quality Improvement | Health Information Technology | Role of Management | Patient Centred Care | New Technology | National Strategy | World Health Organisation | Cross National Learning

An introduction to Ai. Modules cover: Machine Learning | Natural Language Processing | Text Processing | Natural Language Processing | Image Processing | Working with Images & Video | Introduction to Bots | Building Intelligent Bots